title: ErbB2 trafficking and degradation associated with K48 and K63 polyubiquitination.
abstract: The overexpressed ErbB2/HER2 receptor is a clinically validated cancer target whose surface localization and internalization mechanisms remain poorly understood. Downregulation of the overexpressed 185-kDa ErbB2 receptor is rapidly (2-6 hours) induced by the HSP90 chaperone inhibitor geldanamycin (GA), whereas its downregulation and lysosomal degradation are more slowly (24 hours) induced by the proteasome inhibitor bortezomib/PS341. In PS341-treated SK-BR-3 cells, overexpressed ErbB2 coprecipitates with the E3 ubiquitin ligase c-Cbl and also with the deubiquitinating enzyme USP9x; moreover, siRNA downregulation of USP9x enhances PS341-induced ErbB2 downregulation. Because polyubiquitin linkages via lysine 48 (K48) or 63 (K63) can differentially address proteins for 26S proteasomal degradation or endosome trafficking to the lysosome, multiple reaction monitoring (MRM)/mass spectrometry (MS) and polyubiquitin linkage-specific antibodies were used to quantitatively track K48-linked and K63-linked ErbB2 polyubiquitination following either GA or PS341 treatment of SK-BR-3 cells. MRM/MS revealed that unlike the rapid, modest (4-fold to 8-fold), and synchronous GA induction of K48 and K63 polyubiquitinated ErbB2, PS341 produces a dramatic (20-fold to 40-fold) sequential increase in polyubiquitinated ErbB2 consistent with K48 polyubiquitination followed by K63 editing. Fluorescence microscopic imaging confirmed that PS341, but not GA, induces colocalization of K48-linked and K63-linked polyubiquitin with perinuclear lysosome-sequestered ErbB2. Thus, ErbB2 surface overexpression and recycling seem to depend on its polyubiquitination and deubiquitination; as well, the contrasting effects of PS341 and GA on ErbB2 receptor localization, polyubiquitination, and degradation point to alternate cytoplasmic trafficking likely regulated by different K48 and K63 polyubiquitin editing mechanisms.
authors.affiliation: Buck Institute for Age Research, Novato, California 94945, USA.
authors.forename: Corina
authors.initials: C
authors.lastname: Marx
authors.forename: Jason M
authors.initials: JM
authors.lastname: Held
authors.forename: Bradford W
authors.initials: BW
authors.lastname: Gibson
authors.forename: Christopher C
authors.initials: CC
authors.lastname: Benz
mesh_terms: D016227:Benzoquinones / Q000494:pharmacology; D001897:Boronic Acids / Q000494:pharmacology; D000069286:Bortezomib; D001943:Breast Neoplasms / Q000201:enzymology; D045744:Cell Line, Tumor; D002966:Clathrin / Q000378:metabolism; D015536:Down-Regulation; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D006801:Humans; D047029:Lactams, Macrocyclic / Q000494:pharmacology; D008247:Lysosomes / Q000201:enzymology / Q000378:metabolism; D013058:Mass Spectrometry / Q000379:methods; D008856:Microscopy, Fluorescence; D011480:Protease Inhibitors / Q000494:pharmacology; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D061988:Proteasome Inhibitors; D011719:Pyrazines / Q000494:pharmacology; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis / Q000378:metabolism*; D054875:Ubiquitination
chemical_list: D016227:Benzoquinones; D001897:Boronic Acids; D000069286:Bortezomib; D002966:Clathrin; D018841:HSP90 Heat-Shock Proteins; D047029:Lactams, Macrocyclic; D011480:Protease Inhibitors; D046988:Proteasome Endopeptidase Complex; D061988:Proteasome Inhibitors; D011719:Pyrazines; D018719:Erb-b2 Receptor Tyrosine Kinases; C001277:geldanamycin
references.citation: BMC Struct Biol. 2008 May 16;8:26
references.pmid: 18485199
references.citation: J Cell Biol. 2009 May 4;185(3):493-502
references.pmid: 19398763
references.citation: Mol Biol Cell. 2007 Oct;18(10):3952-65
references.pmid: 17686993
references.citation: Cancer Res. 2000 Jul 1;60(13):3384-8
references.pmid: 10910043
references.citation: Nat Cell Biol. 2005 Aug;7(8):750-7
references.pmid: 16056266
references.citation: Mol Biol Cell. 2004 Apr;15(4):1557-67
references.pmid: 14742716
references.citation: J Biol Chem. 2000 Aug 25;275(34):26625-31
references.pmid: 10862618
references.citation: Cancer Res. 2008 Jul 15;68(14):5669-77
references.pmid: 18632619
references.citation: Cell Div. 2007 Mar 13;2:11
references.pmid: 17355622
references.citation: Exp Cell Res. 2008 Oct 15;314(17):3093-106
references.pmid: 18793634
references.citation: Histochem Cell Biol. 2008 May;129(5):563-78
references.pmid: 18288481
references.citation: Clin Breast Cancer. 2008 Oct;8(5):392-401
references.pmid: 18952552
references.citation: Mol Biol Cell. 2004 Apr;15(4):1591-9
references.pmid: 14742711
references.citation: Mol Cancer Res. 2008 Mar;6(3):491-500
references.pmid: 18337455
references.citation: Am J Physiol Endocrinol Metab. 2009 May;296(5):E973-84
references.pmid: 19240253
references.citation: J Cell Biol. 2006 May 22;173(4):463-8
references.pmid: 16702236
references.citation: Cancer Biol Ther. 2008 Oct;7(10):1630-40
references.pmid: 18769124
references.citation: Mol Cell Biol. 2008 Aug;28(15):4805-18
references.pmid: 18519587
references.citation: Mol Cell Biol. 2007 Jul;27(13):5029-39
references.pmid: 17452457
references.citation: Cell Cycle. 2004 Jan;3(1):51-60
references.pmid: 14657666
references.citation: J Neurosci. 2005 Feb 23;25(8):2002-9
references.pmid: 15728840
references.citation: Nature. 1997 Feb 20;385(6618):737-40
references.pmid: 9034192
references.citation: Mol Cell. 2006 Mar 17;21(6):737-48
references.pmid: 16543144
references.citation: J Cell Sci. 2008 Oct 1;121(Pt 19):3155-66
references.pmid: 18765569
references.citation: Mol Biol Cell. 2007 Sep;18(9):3656-66
references.pmid: 17626164
references.citation: Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12847-52
references.pmid: 12239347
references.citation: Cell. 2008 Aug 22;134(4):668-78
references.pmid: 18724939
references.citation: Nat Rev Cancer. 2009 Jul;9(7):463-75
references.pmid: 19536107
references.citation: Mol Biol Cell. 2009 Apr;20(7):2015-29
references.pmid: 19176755
references.citation: Nat Cell Biol. 2006 Jul;8(7):700-10
references.pmid: 16799550
references.citation: J Biol Chem. 1996 Sep 13;271(37):22796-801
references.pmid: 8798456
references.citation: Cancer Res. 2008 Nov 15;68(22):9280-90
references.pmid: 19010901
references.citation: Mol Pharmacol. 2007 Jun;71(6):1525-34
references.pmid: 17392524
references.citation: Cancer Res. 2006 Jul 1;66(13):6732-40
references.pmid: 16818648
references.citation: J Biol Chem. 2003 Apr 18;278(16):13829-37
references.pmid: 12574167
references.citation: Mol Biol Cell. 2004 Dec;15(12):5268-82
references.pmid: 15385631